Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study

Trial Profile

Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms ESTIT
  • Most Recent Events

    • 17 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 14 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top